Compare Emerson Electric Co. (EMR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Medpace Holdings Inc — how do they compare? Emerson Electric Co. trades at $161.83 (market cap $88.72B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Emerson Electric Co. is far larger — about 5.3× Medpace Holdings Inc's market cap, and Emerson Electric Co. pays a 1.4% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Medpace Holdings Inc for 14 Days on average.
| EMR | MEDP | |
|---|---|---|
Market Cap | $88.72B | $16.82B |
Volume | 2,355,255 | 223,093 |
Sector | Industrials | Health |
52-Week High | $164.38 | $630.19 |
52-Week Low | $123.30 | $393.42 |
Typical Hold Time | 81 Days | 14 Days |
Enterprise Value | $99.80B | $16.44B |
Dividend Yield | 1.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $161.83, up 1.64% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 13.83% net income margin and a 12.81% ROE. Revenue is projected to grow to $18.6B in 2026, and the company maintains a solid balance sheet with $3.59B in cash. Analysts are largely positive, with a consensus price target of $165.90.
EMR presents a favorable outlook with upward earnings momentum and analyst support, though valuation multiples like a P/E of 34.81 suggest premium pricing. Risks include competitive pressures and macroeconomic volatility. The stock remains a candidate for growth-oriented investors seeking industrial sector exposure.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
